IDS-iSYS Salivary Cortisol Hypertension Assay Now Available
Immunodiagnostic Systems Holdings plc (IDS), a leading solution provider to the clinical laboratory diagnostic market, today announced the launch of the IDS-iSYS Salivary Cortisol assay in Europe and other markets outside USA. The IDS-iSYS Salivary Cortisol is a fully automated assay for use with the IDS-iSYS Multi-Discipline Automated System family.
The launch of this assay enhances the IDS-iSYS Hypertension panel, which currently includes the automated IDS-iSYS Aldosterone and Direct Renin immunoassays. Together with the planned addition of the of two new tests in 2016, the IDS-iSYS Cortisol (use in human serum, plasma and urine) and the IDS-iSYS ACTH (Adrenocorticotropic hormone), laboratories can consolidate the assessment of endocrine hypertension with Cushing’s syndrome (CS) and other disturbances of the hypothalamic pituitary adrenal axis.
The IDS-iSYS Salivary Cortisol is the only assay in the clinical laboratory industry combining the speed and accuracy of an automated platform, excellent assay sensitivity, precision and traceability to the gold-standard method of Isotope Dilution Mass Spectrometry (ID-MS).
Cortisol is a steroid hormone synthesised in the cortex of the adrenal gland which plays a role in the metabolism of carbohydrates, fat and protein, the maintenance of normal circulatory function, and the adaptation to stress1. In healthy subjects, cortisol levels peak in the early morning and fall for the rest of the day. Patients with abnormal function of the adrenal gland lose this normal circadian rhythm and have higher levels of cortisol at midnight4,5. Approximately 90% of cortisol in plasma or serum is protein bound to cortisol-binding-globulin. Measurement of unbound cortisol found in saliva is an accurate method to assess the biologically active free plasma cortisol2,3. Measuring late night salivary cortisol is an easy and non-invasive means for diagnosing diseases of cortisol imbalance such as Cushing’s (CS). Salivary cortisol is useful as the initial test when CS is suspected and for the periodic monitoring of patients after pituitary surgery6,7.
- John J. Bray et al. Lecture notes on human physiology. Third Edition Published by Blackwell Science 1994.
- David W., The Immunoassay Handbook. Third Edition. D.Wild (Ed.) Published by Elsevier Ltd. 2005.
- Yaneva M., Mosnier-Pudar H., Dugue M-A., Grabar S., Fulla Y. and Bertagna X., ‘Midnight salivary cortisol for the initial diagnosis of Cushing’s syndrome and various causes’. J Clin Endocrinol Metab, 89(7), 2004, pp 3345-3351.
- Raff H. Utility of salivary cortisol measurements in Cushing’s syndrome and adrenal insufficiency. J Clin Endocrinol Metab, 94(10), 2009, pp 3647-3655.
- Nieman LK., Biller BMK., Findling JW., Newell-Price J., Savage MO., Stewart PM., and Montori VM., ‘The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline’. J Clin Endocrinol Metab, 93, 2008, pp 1526-1540.
- Raff, H., ‘Cushing’s syndrome: diagnosis and surveillance using salivary cortisol’. Pituitary, 15, 2012, pp 64-70.
- Raff, H., ‘Update on late-night salivary cortisol for the diagnosis of Cushing’s syndrome: methodological considerations’. Endocrine, 44, 2013, pp 346-349.
For more information about this assay please contact your local sales representative or contact:
Email: [email protected]
Telephone: +44(0) 191 519 6155